Legend Biotech Corp (LEGN) Stock Forecast Nov. 10, 2026
Analysis updated on Nov. 10, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Legend Biotech Corp (LEGN) stock forecast summary
Our AI scores Legend Biotech Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Legend Biotech Corp is a mid-cap company with a market capitalization of $4.49B. It ranks number 59 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For LEGN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -5.0%, measured on 358 forecast dates between 2022-08-23 and 2026-08-12 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -2.0%, measured on 400 forecast dates between 2022-08-23 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +6.4%, buy ≥ +4.3%, sell < +2.2%, strong sell < +0.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-09 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LEGN included.
LEGN price chart and AI forecast
How LEGN ranks among 4224 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Legend Biotech Corp (LEGN) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | LEGN | Rank |
|---|---|---|
| Market Cap | $4.49B | 59/60 |
| EPS | $-1.53 | – |
| Revenue/Share | $7.30 | – |
| FCF/Share | $-2.52 | – |
Profitability & Margins
| Metric | LEGN | Rank |
|---|---|---|
| Gross Margin | 50.0% | 33/36 |
| EBT Margin | -40.4% | 39/46 |
| Tax Rate | -3.1% | – |
Financial Health
| Metric | LEGN | Rank |
|---|---|---|
| Current Ratio | 1.96x | 38/58 |
| Quick Ratio | 1.91x | 20/43 |
| Working Capital | $611M | 38/58 |
Cash Flow
| Metric | LEGN | Rank |
|---|---|---|
| Operating Cash Flow | -$409M | 53/59 |
| Free Cash Flow | -$467M | 45/50 |
| Capital Spending | -$58M | 26/50 |
| FCF/Sales | -34.6% | 36/42 |
| CapEx/Sales | 4.3% | 14/42 |
Operational Efficiency
| Metric | LEGN | Rank |
|---|---|---|
| Asset Turnover | 0.78x | 9/39 |
| Inventory Turnover | 21.1x | 2/35 |
| Fixed Assets Turnover | 11.6x | 17/41 |
| Days Inventory | 17 days | 34/35 |
Income Statement
| Metric | LEGN | Rank |
|---|---|---|
| Total Revenue | $1.35B | 30/46 |
| R&D Expense | $728M | 25/58 |
| Cost of Goods Sold | $675M | 23/37 |
Dividend & Shareholder Information
| Metric | LEGN | Rank |
|---|---|---|
| Shares Outstanding | 185M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.25B | |
| Cash & Short-term Investments | $902M | |
| Inventory | $32M | |
| Total Liabilities | $732M |
LEGN quarterly financials and insider trading
Legend Biotech Corp (LEGN) industry peers
Companies classified under the same SEC industry code as Legend Biotech Corp (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| LEGN Legend Biotech Corp | $4.49B | |
| LLY Eli Lilly & Co | $1.33T | |
| JNJ Johnson & Johnson | $679.13B | |
| ABBV Abbvie Inc. | $518.30B | |
| MRK Merck & Co., Inc. | $367.02B | |
| NVS Novartis Ag | $310.17B | |
| AZN Astrazeneca Plc | $293.55B | |
| ABT Abbott Laboratories | $192.16B | |
| NVO Novo Nordisk A S | $179.14B | |
| PFE Pfizer Inc | $167.51B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $138.67B | |
| BMY Bristol Myers Squibb Co | $127.02B | |
| SNY Sanofi | $115.97B | |
| GSK Gsk Plc | $103.98B | |
| REGN Regeneron Pharmaceuticals, Inc. | $93.11B | |
| TAK Takeda Pharmaceutical Co Ltd | $65.66B | |
| TEVA Teva Pharmaceutical Industries Ltd | $49.65B | |
| ONC Beone Medicines Ltd. | $46.26B | |
| GMAB Genmab A/S | $35.90B | |
| ZTS Zoetis Inc. | $32.81B | |
| RPRX Royalty Pharma Plc | $28.82B | |
| ROIV Roivant Sciences Ltd. | $28.08B | |
| INSM Insmed Inc | $25.47B | |
| UTHR United Therapeutics Corp | $24.11B | |
| VTRS Viatris Inc | $22.87B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.98B | |
| ASND Ascendis Pharma A/S | $17.07B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.81B | |
| BBIO Bridgebio Pharma, Inc. | $15.18B | |
| ELAN Elanco Animal Health Inc | $13.41B | |
| SMMT Summit Therapeutics Inc. | $13.03B | |
| RDY Dr Reddys Laboratories Ltd | $12.44B | |
| BMRN Biomarin Pharmaceutical Inc | $11.07B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $10.00B | |
| TGTX Tg Therapeutics, Inc. | $9.49B | |
| SYRE Spyre Therapeutics, Inc. | $9.16B | |
| PTGX Protagonist Therapeutics, Inc | $8.54B | |
| CORT Corcept Therapeutics Inc | $8.11B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.76B | |
| PRAX Praxis Precision Medicines, Inc. | $7.75B | |
| ALKS Alkermes Plc. | $7.75B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.73B | |
| CYTK Cytokinetics Inc | $7.67B | |
| AXSM Axsome Therapeutics, Inc. | $7.02B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $6.96B | |
| ABVX Abivax S.A. | $6.83B | |
| ORKA Oruka Therapeutics, Inc. | $6.81B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.80B | |
| LGND Ligand Pharmaceuticals Inc | $6.28B | |
| BLTE Belite Bio, Inc | $6.20B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.05B | |
| MANE Veradermics, Inc | $6.01B | |
| COGT Cogent Biosciences, Inc. | $5.82B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| PTCT Ptc Therapeutics, Inc. | $5.47B | |
| ERAS Erasca, Inc. | $5.46B | |
| EWTX Edgewise Therapeutics, Inc. | $5.29B | |
| IONS Ionis Pharmaceuticals Inc | $5.15B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $5.03B | |
| TVTX Travere Therapeutics, Inc. | $4.44B |
Where LEGN sits on the market map
Legend Biotech Corp (LEGN) stock news
Loading...
Legend Biotech Corp (LEGN) stock forecast FAQ
What is the Legend Biotech Corp (LEGN) stock forecast?
Our AI scores Legend Biotech Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Legend Biotech Corp stock predictions?
For LEGN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -5.0%, measured on 358 forecast dates between 2022-08-23 and 2026-08-12 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -2.0%, measured on 400 forecast dates between 2022-08-23 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Legend Biotech Corp forecasts updated?
Legend Biotech Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 10, 2026.
Which companies are Legend Biotech Corp's industry peers?
60 issuers in our coverage, LEGN included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.